 Calcitonin gene-related peptide, CGRP, targeted monoclonal antibodies, MABS, have been shown to be effective and safe in treating migraines. However, some patients do not respond to this treatment, which can lead to frustration and uncertainty about what factors may influence response. Studies suggest that certain characteristics such as obesity, interictal allodynia, and the presence of daily headaches may indicate a poor response to CGRP MABS. In contrast, having tried other prophylactic medications, unilateral pain with or without unilateral autonomic symptoms, and a history of successful treatment with triptan drugs may indicate a good response to CGRP MABS. Further research is needed to confirm these findings and develop more personalized treatment strategies for patients with migraine. This article was authored by Jubin Hong, Kristin Sophie Lange, Lucas Hendrick Overeem and others. We are article.tv, links in the description below.